Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 3, 2015, Pages 731-738

  Nguyen, Thi Thu Nga ^a,b,c   Rato, Sylvie ^a   Molina, Jean Michel ^a,b,c   Clavel, François ^a,b,c   Delaugerre, Constance ^a,b,c   Mammano, Fabrizio ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Evolution; Integrase strand transfer inhibitors; Resistance mechanisms

Indexed keywords

RALTEGRAVIR; 2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTEGRASE;

ANTIBIOTIC RESISTANCE; ARTICLE; CASE REPORT; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; INTERVENTION STUDY; MOLECULAR CLONING; PHENOTYPE; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; BIOSYNTHESIS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; MISSENSE MUTATION; PHYSIOLOGY;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV; HIV INTEGRASE; HUMANS; MUTATION, MISSENSE; PYRROLIDINONES; VIRUS REPLICATION;

EID: 84924129857     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku424     Document Type: Article

References (29)

1. Grant P, Zolopa A. Integrase inhibitors: a clinical review of raltegravir and elvitegravir. J HIV Ther 2008; 13: 36-9.
2. Hazuda DJ. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287: 646-50.
3. Lennox JL, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravirbased versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796-806.
4. Raffi F, Rachlis A, Stellbrink H-J et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381: 735-43.
5. Sax PE, DeJesus E, Mills A et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379: 2439-48.
6. DeJesus E, Rockstroh JK, Henry K et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379:2429-38.
7. Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339-54.
8. Steigbigel RT, Cooper DA, Teppler H et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010; 50: 605-12.
9. Cahn P, Pozniak AL, Mingrone H et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013; 382: 700-8.
10. Molina J-M, LaMarca A, Andrade-Villanueva J et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatmentexperienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012; 12: 27-35.
11. Cooper DA, Steigbigel RT, Gatell JM et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355-65.
12. Canducci F, Sampaolo M, Marinozzi MC et al. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 2009; 23:455-60.
13. da Silva D, Van Wesenbeeck L, Breilh D et al. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 2010; 65: 1262-9.
14. Ferns RB, Kirk S, Bennett J et al. The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. AIDS 2009; 23: 2159-64.
15. Fransen S, Karmochkine M, Huang W et al. Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrob Agents Chemother 2009; 53: 4522-4.
16. Hatano H, Lampiris H, Fransen S et al. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 54: 389-93.
17. Malet I, Delelis O, Soulie C et al. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother 2009; 63: 795-804.
18. Sichtig N, Sierra S, Kaiser R et al. Evolution of raltegravir resistance during therapy. J Antimicrob Chemother 2009; 64: 25-32.
19. Blanco JL, Varghese V, Rhee SY et al. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011; 203: 1204-14.
20. Hurt CB, Sebastian J, Hicks CB et al. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis 2014; 58: 423-31.
21. Fransen S, Gupta S, Danovich R et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 2009; 83: 11440-6.
22. Nguyen HL, Charpentier C, Nguyen N et al. Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravirbased regimens. HIV Med 2013; 14: 85-91.
23. Maréchal V, Clavel F, Heard JM et al. Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J Virol 1998; 72:2208-12.
24. Perrin V, Mammano F. Parameters driving the selection of nelfinavirresistant human immunodeficiency virus type 1 variants. J Virol 2003; 77:10172-5.
25. Mammano F, Trouplin V, Zennou V et al. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol 2000; 74: 8524-31.
26. Quercia R, Dam E, Perez-Bercoff D et al. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol 2009; 83: 10245-9.
27. KeulenW, Boucher C, Berkhout B. Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins. Antiviral Res 1996; 31: 45-57.
28. Abram ME, Ferris AL, Shao Wet al. Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J Virol 2010; 84:9864-78.
29. Keulen W, Back NK, van Wijk A et al. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol 1997; 71: 3346-50.